The Servier laboratory is giving itself three years to establish itself in the treatment of cancer

Launching an innovative drug every three years is the challenge that Servier is setting itself up by 2025. The second French laboratory (behind Sanofi), whose image has long been damaged by the Mediator affair, now wants to play in the big leagues.

Already world number 5 in cardiology, it intends to accelerate in oncology and "

become a recognized player

" in this field, with a billion euros in turnover by 2025, according to its president, Olivier Laureau.

By this time, Servier hopes to achieve 6.5 billion euros in turnover (4.7 billion in 2020).

Read also:

Ten years after the Mediator affair, Servier continues to evolve

The task does not look easy.

Its cancer treatments (Onivyde, Oncaspar, Lonsurf) represent only 10% of its sales.

Servier has to compete with industry giants such as MSD, Roche or BMS.

“

Faced with large pharmaceutical labs, we are forced to focus our efforts,

insists Claude Bertrand, who heads R&D at Servier.

We have chosen to rely primarily on monoclonal antibodies

This article is for subscribers only.

You have 66% left to discover.

Subscribe: 1 € the first month

Can be canceled at any time

I ENJOY IT

Already subscribed?

Log in